APAptus Pharma544529Quarterly results

Aptus Pharma reports H1 2026-27 revenue of ₹48.92 crore, targets own manufacturing, exports and Pan-India reach by 2029

H1 2026-27 revenue ₹48.92 crore, nearly twofold YoY; EBITDA ₹7.68 crore, PAT over ₹5.07 crore.

By ScoutQuest · Fri 23 Oct 2026, 5:32 PM IST · 1 min read

H1 2026-27 revenue

₹48.92 crore

EBITDA

₹7.68 crore

PAT

over ₹5.07 crore

Period

H1 2026 - 27

Positioning

Aptus Pharma says it is a fast-growing, BSE SME-listed Indian pharma brand company with 300+ formulations across Pharma Formulation, OTC and Global verticals, using WHO-GMP certified manufacturers.

📈 Aptus reports H1 2026-27 revenue of ₹48.92 crore, EBITDA of ₹7.68 crore and PAT of over ₹5.07 crore, which the managing director describes as nearly twofold year-on-year revenue growth. Revenue crossed ₹46 crore in FY26.

📌 The company positions itself as moving from a regional to a national player with 300+ formulations; acute therapy is approx 44% of sales, while chronic, wellness & OTC and services together contribute 56%.

🏭 Management states it is targeting 46% geographic coverage across India by March 2027 and a Pan-India footprint by March 2029, and the presentation lists global expansion into Asia, Africa and Latin America by March 2028.

🏭 The company says it targets 20% own manufacturing by 2028 and aims to become an integrated manufacturing and export-focused company, pursuing expansion in a phased manner subject to market conditions and regulatory requirements.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev